Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model

2012 ◽  
Vol 92 (1) ◽  
pp. 175-184 ◽  
Author(s):  
Meena Sharma ◽  
Marc R. Blackman ◽  
Mahesh C. Sharma
2018 ◽  
Vol 13 (11) ◽  
pp. 1447-1457 ◽  
Author(s):  
Haoqiang Lai ◽  
Xiaoyan Fu ◽  
Chengcheng Sang ◽  
Liyuan Hou ◽  
Pengju Feng ◽  
...  

2013 ◽  
Vol 110 (17) ◽  
pp. 6991-6996 ◽  
Author(s):  
J. L. Green ◽  
J. La ◽  
K. W. Yum ◽  
P. Desai ◽  
L.-W. Rodewald ◽  
...  

2012 ◽  
Vol 26 (3) ◽  
pp. 285-298 ◽  
Author(s):  
Lu Jiang ◽  
Tiffany R. Greenwood ◽  
Erika R. Amstalden van Hove ◽  
Kamila Chughtai ◽  
Venu Raman ◽  
...  

2011 ◽  
Vol 208 (3) ◽  
pp. 479-490 ◽  
Author(s):  
Alexander Pedroza-Gonzalez ◽  
Kangling Xu ◽  
Te-Chia Wu ◽  
Caroline Aspord ◽  
Sasha Tindle ◽  
...  

The human breast tumor microenvironment can display features of T helper type 2 (Th2) inflammation, and Th2 inflammation can promote tumor development. However, the molecular and cellular mechanisms contributing to Th2 inflammation in breast tumors remain unclear. Here, we show that human breast cancer cells produce thymic stromal lymphopoietin (TSLP). Breast tumor supernatants, in a TSLP-dependent manner, induce expression of OX40L on dendritic cells (DCs). OX40L+ DCs are found in primary breast tumor infiltrates. OX40L+ DCs drive development of inflammatory Th2 cells producing interleukin-13 and tumor necrosis factor in vitro. Antibodies neutralizing TSLP or OX40L inhibit breast tumor growth and interleukin-13 production in a xenograft model. Thus, breast cancer cell–derived TSLP contributes to the inflammatory Th2 microenvironment conducive to breast tumor development by inducing OX40L expression on DCs.


1997 ◽  
Vol 6 (6) ◽  
pp. 353-360 ◽  
Author(s):  
Majella S. de Lange ◽  
Bert Top ◽  
Caro Lambrechts ◽  
Riks A. Maas ◽  
Hans L. Peterse ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document